NCT01640730终止2 期
An Open Label Safety and Exploratory Efficacy Study of Kanglaite Injection in Patients Having Progressive Stage IV NSCLC Who Are Not Candidates for Other Anti-cancer Treatment
KangLaiTe USA1 个研究点 分布在 1 个国家目标入组 1 人开始时间: 2012年5月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 终止
- 发起方
- 入组人数
- 1
- 试验地点
- 1
- 主要终点
- Overall Survival
研究概览
简要总结
This study is for patients with advanced non small cell lung cancer that has progressed despite standard of care. The purpose of the study is to see if Kanglaite injection has any effect on survival.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •confirmed (within last 3 months)progressive Stage IV NSCLC
- •estimated life span of 3 months
- •phase angle of at least 5 as measured by bioimpedance
排除标准
- •currently taking a lipid lowering medications
- •has an imminently life threatening condition
- •has pre-existing liver disease
- •known allergy to soybeans
- •uncontrolled diabetes or uncontrolled disturbance of lipid metabolism
- •pregnant or lactating
- •has a pacemaker or other implantable electronic medical device
研究组 & 干预措施
Kanglaite injection
Experimental
干预措施: Kanglaite Injection (Drug)
结局指标
主要结局
Overall Survival
时间窗: from date of enrollment until date of death from any cause assessed up to 12 months
次要结局
- Bioimpedance Phase Angle(measured each month up to one year)
- Palliation Response Measure(each month up to one year)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Effect of Talactoferrin in Adults With Non-Small Cell Lung CancerNon-Small Cell Lung CancerNCT00923741National Cancer Institute (NCI)10
终止
2 期
KN046 in Patients With Advanced Non-small Cell Lung CancerStage IV Non-small Cell Lung CancerNCT03838848Jiangsu Alphamab Biopharmaceuticals Co., Ltd120
已完成
2 期
Clinical Trial of the Safety and Efficacy of the Addition of Ramucirumab to Nab-paclitaxel in Previously Treated Patients With Advanced Non-small Cell Lung Cancer (NSCLC)Non-small Cell Lung CancerNCT02730247Liza Villaruz, MD7
终止
1 期
A Study of Ramucirumab (LY3009806) Given by Injection Under the Skin in Participants With Advanced CancerAdvanced Solid TumorNCT04557384Eli Lilly and Company3
撤回
1 期
Phase I Study of SPH1188-11 in NSCLCNSCLC Stage IIIBNSCLC Stage IVNCT03231475Shanghai Pharmaceuticals Holding Co., Ltd